bluebird bio
BLUENASDAQDelistedLentiviral gene therapy platform
Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.
text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from
Pipeline at the time of the last update
| Drug | Indication | Phase | Expected data | |
|---|---|---|---|---|
| Lyfgenia | sickle cell disease | Approved | Not disclosed | ▼ |
| Zynteglo | transfusion-dependent beta thalassemia | Approved | Not disclosed | ▼ |
| Skysona | cerebral adrenoleukodystrophy | Approved | Not disclosed | ▼ |
Comparable companies
Sarepta TherapeuticsCRISPR TherapeuticsRocket Pharmaceuticals
Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.